|
|
|
|
|
Flurbiprofen
drug data and news
Flurbiprofen drug data, resources, and news articles (when available). Onconews.org provides news on cancer research. This section, which includes profiles on medicines that may or not be cancer-related is in beta form. If things run smoothly we will be releasing a new format late in the summer of 2006.
|
| Generic name | Flurbiprofen | ||
| Brand Names/Synonyms | Adfeed; Ansaid; Antadys; Apo-Flurbiprofen; Cebutid; FLP; Flurbiprofen; Flurbiprofen Axetil; Flurbiprofen Sodium; Flurbiprofene [Inn-French]; Flurbiprofeno [Inn-Spanish]; Flurbiprofenum [Inn-Latin]; Flurofen; Froben; Froben Sr; Novo-Flurprofen; Nu-Flurbiprofen; Ocufen; Stayban; Zepolas | ||
| Indication | Flurbiprofen tablets are indicated for the acute or long-term treatment of the signs and symptoms of rheumatoid arthritis and osteorarthritis. | ||
| Sponsored links | Description | Not Available | |
| Pharmacology | Flurbiprofen, a nonsteroidal antiinflammatory drug (NSAID) of the propionic acid class, is used for the relief of pain and inflammation associated with rheumatoid arthritis and osteoarthritis and for the inhibition of intraoperative miosis. Flurbiprofen exhibits antiinflammatory, analgesic, and antipyretic activities. | ||
| Mechanism Of Action | The antiinflammatory effect of flurbiprofen may result from the reversible inhibition of cyclooxygenase, causing the peripheral inhibition of prostaglandin synthesis. Flurbiprofen also inhibits the migration of leukocytes into sites of inflammation and prevents the formation of thromboxane A2, an aggregating agent, by the platelets. | ||
| Flurbiprofen News (When available) |
Alzheimer's Disease drug trial to touch the Tampa Bay area Jan 21, 2006 Drug Treatments and Lifestyle Based Interventions Share Spotlight ... Sep 10, 2005 Omega-6 fatty acids cause prostate tumor cell growth in culture Sep 2, 2005 Omega-6 fatty acids cause prostate tumor cell growth in culture Aug 1, 2005 Consider HCT 1026 for very young autistic infants and toddlers ... Jul 29, 2005 Clinical trial shows promise with NicOx nitric oxide-donating ... Jul 12, 2005 GLOBAL PHARMACEUTICALS Jul 14, 2005 NicOx osteoporosis drug shows potential Jul 12, 2005 Ispronicline Joins Effort to Find Alzheimer’s Cure Jul 6, 2005 Clinical Trial Shows Promise With NicOx Nitric Oxide-Donating ... 11 Jul 2005 New approach in the treatment of Alzheimer’s disease Jul 2, 2005 First Alzheimer’s conference showcases research Jun 19, 2005 Alzheimer's Treatment Innovations Show Promise Jun 20, 2005 Innovative therapies for Alzheimer's Jun 20, 2005 Alzhemed Resumes Race for Alzheimer’s Cure with Phase III Trial Jul 5, 2005 Therapies may help Alzheimer's substance Jun 20, 2005 Antibodies, drug, exercise provide Alzheimers hope Jun 20, 2005 Three novel therapies could slow progress of Alzheimer's Jun 20, 2005 New therapies may slow Alzheimer's Jun 21, 2005 Folic acid may slow mental decline, scientists say Jun 20, 2005 First Alzheimer’s conference showcases research Jun 20, 2005 Alzheimer's Treatment Innovations Show Promise Jun 20, 2005 Innovative therapies for Alzheimer's Jun 20, 2005 Is Flurizan the Alzheimer’s Treatment the World Awaits? Jun 21, 2005 Therapies may help Alzheimer's substance Jun 20, 2005 Antibodies, drug, exercise provide Alzheimers hope Jun 20, 2005 Three novel therapies could slow progress of Alzheimer's Jun 20, 2005 New therapies may slow Alzheimer's Jun 21, 2005 Folic acid may slow mental decline, scientists say Jun 20, 2005 Topical Nonsteroidal Anti-inflammatory Drugs for Corneal Abrasions ... Apr 28, 2005 Topical Nonsteroidal Anti-inflammatory Drugs for Corneal Abrasions ... 29 Apr 2005 Alzhemed and Flurizan Will be Primary Drivers in Doubling Market ... Mar 28, 2005 NicOx Reports 2004 Financial Results Mar 1, 2005 | ||
| Dosage Forms | CAPSULE (SUSTAINED-RELEASE); LIQUID; TABLET | ||
| Drug_Category | Anti-inflammatory Agents; Analgesics; Nonsteroidal Antiinflammatory Agents (NSAIDs); Carbonic Anhydrase Inhibitors; Cyclooxygenase Inhibitors; ATC:M01AE09; ATC:M02AA19; ATC:S01BC04 | ||
| Absorption | The mean oral bioavailability of flurbiprofen from tablets is 96% relative to an oral solution. | ||
| Interactions |
Interactions for Flurbiprofen: Antacids: Administration of flurbiprofen to volunteers under fasting conditions, or with antacid suspension yielded similar serum flurbiprofen time profiles in young subjects (n=12). In geriatric subjects (n=7) there was a reduction in the rate but not the extent of flurbiprofen absorption. Anticoagulants: Flurbiprofen like other nonsteroidal anti-inflammatory drugs, has been shown to affect bleeding parameters in patients receiving anti-coagulants, and serious clinical bleeding has been reported. The physician should be cautious when administering flurbiprofen to patients taking anticoagulants. Aspirin: Concurrent administration of aspirin and flurbiprofen resulted in 50% lower serum flurbiprofen concentrations. This effect of aspirin (which also lowers serum concentrations of other nonsteroidal anti-inflammatory drugs given with it) has been demonstrated in patients with rheumatoid arthritis (n= 15) as well as normal volunteers (n= 16). Concurrent use of flurbiprofen and aspirin is therefore not recommended. Beta-adrenergic Blocking Agents: The effect of flurbiprofen on blood pressure response to propranolol and atenolol was evaluated in men with mild uncomplicated hypertension (n = 10). Flurbiprofen pretreatment attenuated the hypotensive effect of a single dose of propranolol but not atenolol. Flurbiprofen did not appear to affect the beta-blocker-mediated reduction in heart rate. Flurbiprofen did not affect the pharmacokinetic profile of either drug, and the mechanism under lying the interference with propranolol's hypotensive effect is unknown. Patients taking both flurbiprofen and a beta-blocker should be monitored to ensure that a satisfactory hypotensive effect is achieved. Cimetidine, Ranitidine: In normal volunteers (n=9), pretreatment with cimetidine or ranitidine did not affect flurbiprofen pharmacokinetics except that a small (13 %) but statistically significant increase in the area under the serum concentration curve of flurbiprofen resulted with cimetidine. Digoxin: Studies of concomitant administration of flurbiprofen and digoxin to healthy men (n= 14) did not show a change in the steady state serum levels of either drug. Diuretics: Studies in normal volunteers have shown that flurbiprofen like other nonsteroidal anti-inflammatory drugs, can interfere with the effects of furosemide. Although results have varied from study to study, effects have been shown on furosemide-stimulated diuresis, natriuresis, and kaliuresis. Other nonsteroidal anti-inflammatory drugs that inhibit prostaglandin synthesis have been shown to interfere with thiazide diuretics in some studies and with potassium-sparing diuretics. Patients receiving flurbiprofen and furosemide or other diuretics should be observed closely to determine if the desired effect is obtained. Oral Hypoglycemic Agents: In one study, flurbiprofen was given to adult diabetics who were already
receiving glyburide (n=4), metformin (n=2) chlorpropamide with phenformin (n= 3) or glyburide with phenformin (n=6).
Although there was a slight reduction in blood sugar concentrations during concomitant administration of flurbiprofen
and hypoglycemic agents, there were no signs or symptoms of hypoglycemia. | ||
| Toxicity | Oral, dog LD50: 10 mg/kg. | ||
| Organisms Affected | Humans and other mammals | ||
| Chemical IUPAC Name | 2-(3-fluoro-4-phenyl-phenyl)propanoicacid | ||
| Chemical Formula | C15H13FO2 | ||
| Molecular Weight | 244.261 g/mol | ||
| Smiles String | CC(C1=CC(=C(C=C1)C2=CC=CC=C2)F)C(=O)O | ||
| Melting Point | 110-111 °C | ||
| Water Solubility | 8 mg/L | ||
| State | Solid | ||
| LogP/Hphobicity | 4.078 | ||
| Isoelectric Point | Not Available | ||
| Biotransformation | Hepatic. Cytochrome P450 2C9 plays an important role in the metabolism of flurbiprofen to its major metabolite, 4’-hydroxy-flurbiprofen. The 4’-hydroxy-flurbiprofen metabolite showed little anti-inflammatory activity in animal models of inflammation. | ||
| Half Life | 4.7-5.7 hours | ||
| Protein Binding [%] | > 99% | ||
| RxList Link | RXlist | ||
| Sponsored links | |||
| Drug Reference |
http://www.drugs.com/cons/Flurbiprofen.html http://www.rxlist.com/cgi/generic2/flurbipro.htm http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/ans1023.shtml | ||
| Drug Type | Approved Drug | ||
| Accession No | APRD00753 | ||
| CAS Registry Number | 5104-49-4 | ||
| KEGG Compound ID | C07013 | ||
| PubChem ID | SID:163961 | ||
| PharmGKB ID | PA449683 | ||
| SwissProt ID | Not Available | ||
| GenBank ID | Not Available | ||
| Drug ID Number [DIN] | 2020661 |
|
Home | About | Cancers | Treatment | Medications Copyright onconews.org 2005. All Rights Reserved. |